Silence Therapeutics plc
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
5. Loss per share (basic and diluted)
Basic net loss per share is computed by dividing net loss (the numerator) by the weighted average shares outstanding for the period (the denominator). Diluted net loss per share is computed by dividing net income by the weighted average shares outstanding during the period adjusted for the dilutive effects of the exercise of the stock options. In periods when losses from continuing operations are reported, the weighted-average shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. The computation of net loss per share for the three and six months ended June 30, 2025 and 2024, respectively was as follows:
| Three months ended June 30, | Six months ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| $000s | $000s | $000s | $000s | |
| Net loss | (27,354) | (19,755) | (55,884) | (22,067) |
| Weighted-average shares outstanding (basic and diluted) | 141,696,047 | 140,208,929 | 141,687,438 | 136,045,022 |
| Net loss per share (basic and diluted) | $(0.19) | $(0.14) | $(0.39) | $(0.16) |
The options outstanding at June 30, 2025 and 2024 were considered to be anti-dilutive as the Group is loss-making.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.